Arena Pharma (ARNA) Misses Q3 EPS by 68c

Arena Pharma (NASDAQ: ARNA) reported Q3 EPS of ($3.21), $0.68 worse than the analyst estimate of ($2.53). Revenue for the quarter came in at $0 versus the consensus estimate of $680 thousand.

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c